We found ERK1/2 and its active form pERK1/2 upregulated in all the breast cancer cells examined and their levels remain unchanged with CHX treatment, indicating increased stability of these proteins (Figure 6A). This evidence concerns the gene MAPK3 and breast carcinoma.